According to the Smart Finance app, Sinobiomedicine-B(02257) is now up more than 6%. As of press time, it has risen 4.91%, to HKD 4.49, with a turnover of HKD 6.3089 million.

On the news front, Sinobiomedicine-B recently announced that its Phase I clinical trial has been successfully completed. The study was conducted at 11 cancer clinics across the United States and involved 50 patients with various types of cancer. The results of the study showed that STP707 showed strong safety and stable disease activity in patients.

Dr. Lu Yang, the founder of Sinobiomedicine, stated that as a leading siRNA drug product, STP707 has demonstrated strong safety and efficacy after intravenous administration, which is of great significance for the treatment of metastatic tumors based on RNAi cancer therapy. He emphasized that STP707, whether used as a single agent or in combination with immune checkpoint inhibitors, could become a new type of cancer treatment method.